ReviewFrontiers in systems biology2025
Bridging academia and industry: advancing systems biology and QSP education through AstraZeneca's collaborative partnerships.
Review in Frontiers in systems biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- From Prediction to Decision Making: PBPK and QSP as Regulatory-Grade NAMs.Clinical pharmacology and therapeutics · 2026Review
- A digital twin approach for transforming prescription drug labeling.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Collaborations between industry leaders and academia are crucial for advancing systems biology education and training. This article explores opportunities for partnerships to enhance the educational landscape and develop a workforce skilled in systems modelling, particularly for quantitative systems pharmacology (QSP) in drug development. Companies with a strong focus on innovation frequently explore collaborative ventures involving joint research, co-designed curricula, and specialized training programs. These partnerships provide students and researchers with insights into real-world applications of systems biology and QSP. We explicitly review success criteria for collaboration at MSc and PhD levels, discuss earlier pipeline considerations, and carefully balance the roles, incentives, and challenges for both academia and industry in collaborative ventures. Challenges in aligning academic and industry objectives exist, including resource allocation and intellectual property concerns. However, the importance of training skilled systems biologists for advancing drug discovery and development outweighs these challenges. The article concludes by highlighting successful industry-academia partnerships and offering recommendations for optimizing collaborations to meet the evolving needs of systems biology education and drive innovation in pharmaceutical research.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.